We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+17%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$9.33B
AUM Growth
+$1.78B
(+24%)
Cap. Flow
+$552M
Cap. Flow
% of AUM
5.91%
Top 10 Holdings %
Top 10 Hldgs %
20.52%
Holding
814
New
78
Increased
378
Reduced
271
Closed
33
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$50.3M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$39.4M |
| 3 |
Intel
INTC
|
+$29.2M |
| 4 |
Qualcomm
QCOM
|
+$27.6M |
| 5 |
Danaher
DHR
|
+$26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
+$49.9M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$41.6M |
| 3 |
ARQL
Arqule Inc
ARQL
|
+$26.5M |
| 4 |
Arrowhead Research
ARWR
|
+$24.9M |
| 5 |
Merck
MRK
|
+$15.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 30.73% |
| 2 | Technology | 19.55% |
| 3 | Financials | 10.18% |
| 4 | Consumer Discretionary | 9.32% |
| 5 | Communication Services | 8.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Coherus Oncology
CHRS
$225M
| $6.08M | 0.07% |
337,721
+165,802
| +96% | +$3.06M |
|
302
Church & Dwight Co
CHD
$23.4B
| $6.08M | 0.07% |
86,383
+9,215
| +12% | +$655K |
|
303
Akamai
AKAM
$16.4B
| $6.04M | 0.06% |
69,901
-29,331
| -30% | -$2.56M |
|
304
Illinois Tool Works
ITW
$81.9B
| $6.04M | 0.06% |
33,615
-507
| -1% | -$85.9K |
|
305
Manulife Financial
MFC
$73.2B
| $6.01M | 0.06% |
295,881
+208,418
| +238% | +$3.98M |
|
306
Crown Castle
CCI
$32.4B
| $5.94M | 0.06% |
41,774
-4,196
| -9% | -$572K |
|
307
Omnicom Group
OMC
$23.5B
| $5.89M | 0.06% |
72,679
+35,520
| +96% | +$2.78M |
|
308
Roper Technologies
ROP
$37.1B
| $5.88M | 0.06% |
16,592
+1,204
| +8% | +$416K |
|
309
Canadian National Railway
CNI
$78B
| $5.87M | 0.06% |
64,776
+2,221
| +4% | +$200K |
|
|
CNST
310
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $5.83M | 0.06% |
+123,774
| New | +$3.57M |
|
311
Micron Technology
MU
$1.02T
| $5.83M | 0.06% |
108,345
+3,747
| +4% | +$179K |
|
312
Franklin Resources
BEN
$17.3B
| $5.81M | 0.06% |
223,506
-286,330
| -56% | -$7.78M |
|
313
McCormick & Company Non-Voting
MKC
$13.6B
| $5.8M | 0.06% |
68,342
-10
| -0% | -$828 |
|
|
TSG
314
DELISTED
The Stars Group Inc.
TSG
| $5.76M | 0.06% |
+220,857
| New | +$4.94M |
|
315
Xerox
XRX
$357M
| $5.73M | 0.06% |
155,531
+87,093
| +127% | +$3.05M |
|
316
Devon Energy
DVN
$49.8B
| $5.68M | 0.06% |
218,784
-31,424
| -13% | -$707K |
|
317
Tractor Supply
TSCO
$16.7B
| $5.66M | 0.06% |
303,090
+137,455
| +83% | +$2.61M |
|
318
Charter Communications
CHTR
$15.7B
| $5.63M | 0.06% |
11,601
-17,466
| -60% | -$8.04M |
|
|
K
319
DELISTED
Kellanova
K
| $5.62M | 0.06% |
86,538
+26,851
| +45% | +$1.63M |
|
320
Fortune Brands Innovations
FBIN
$6.14B
| $5.61M | 0.06% |
+100,457
| New | +$5.28M |
|
321
Zoetis
ZTS
$32.2B
| $5.61M | 0.06% |
42,382
+672
| +2% | +$83.5K |
|
322
Phillips 66
PSX
$83.3B
| $5.53M | 0.06% |
49,649
+9,009
| +22% | +$1.01M |
|
323
Veeva Systems
VEEV
$31.6B
| $5.52M | 0.06% |
39,273
+1,762
| +5% | +$259K |
|
324
Sysco
SYY
$40.2B
| $5.51M | 0.06% |
64,381
+3,650
| +6% | +$296K |
|
325
eBay
EBAY
$50.3B
| $5.5M | 0.06% |
152,299
-96,486
| -39% | -$3.5M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q4 2019 Portfolio in Review
As of Q4 2019, Candriam SCA held 814 positions worth $9.33B, up 24% from $7.55B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Candriam SCA deployed $552M of net new capital in Q4 2019, opening 78 new positions and adding to 378 existing holdings. Its largest new stake was Vipshop: 2,005,000 shares worth $28.4M.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 32% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Ra Pharmaceuticals, Inc. Common Stock, an estimated $49.9M trimmed.
- Candriam SCA's largest Q4 2019 buy was Vipshop: 2,005,000 shares worth $28.4M.
- Candriam SCA added most to Microsoft in Q4 2019, an estimated $50.3M increase.
- Candriam SCA's biggest Q4 2019 reduction was Ra Pharmaceuticals, Inc. Common Stock, cutting an estimated $49.9M.
- Candriam SCA fully exited Hilton Worldwide in Q4 2019, selling an estimated $11.8M.
- Candriam SCA's ten largest holdings make up 21% of its $9.33B portfolio in Q4 2019.
- Candriam SCA opened 78 new positions and closed 33 in Q4 2019.
- Candriam SCA's portfolio value rose 24% quarter-over-quarter to $9.33B.
Based on Candriam SCA's 13F filing for Q4 2019, filed 21 Jan 2020.